{"id":"NCT01309646","sponsor":"GlaxoSmithKline","briefTitle":"Immunogenicity and Safety of GlaxoSmithKline Biologicals' Infanrix™-IPV+Hib Vaccine","officialTitle":"Immunogenicity and Safety of GlaxoSmithKline Biologicals' DTPa-IPV/Hib (Infanrix™-IPV+Hib) Vaccine in Healthy Korean Infants","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-03-04","primaryCompletion":"2012-02-24","completion":"2012-02-24","firstPosted":"2011-03-07","resultsPosted":"2013-04-02","lastUpdate":"2019-11-27"},"enrollment":454,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Poliomyelitis","Tetanus","Acellular Pertussis","Diphtheria","Haemophilus Influenzae Type b"],"interventions":[{"type":"BIOLOGICAL","name":"Infanrix™-IPV+Hib","otherNames":[]},{"type":"BIOLOGICAL","name":"Infanrix™ IPV","otherNames":[]},{"type":"BIOLOGICAL","name":"Hiberix™","otherNames":[]},{"type":"BIOLOGICAL","name":"Synflorix™","otherNames":[]},{"type":"BIOLOGICAL","name":"Rotarix™","otherNames":[]}],"arms":[{"label":"Infanrix-IPV+Hib Group","type":"EXPERIMENTAL"},{"label":"Infanrix IPV Group","type":"ACTIVE_COMPARATOR"}],"summary":"This study is designed to evaluate the safety and immunogenicity of Infanrix™-IPV+Hib vaccine when administered as a primary vaccination course to healthy Korean infants at 2, 4 and 6 months of age.","primaryOutcome":{"measure":"Number of Seroprotected Subjects for Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T) Antibodies.","timeFrame":"At Month 5","effectByArm":[{"arm":"Infanrix-IPV+Hib Group","deltaMin":213,"sd":null},{"arm":"Infanrix IPV Group","deltaMin":217,"sd":null}],"pValues":[]},"eligibility":{"minAge":"42 Days","sex":"ALL","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":13},"locations":{"siteCount":11,"countries":["South Korea"]},"refs":{"pmids":["30431387"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":25,"n":224},"commonTop":["Irritability/Fussiness","Redness","Drowsiness","Pain","Swelling"]}}